Online inquiry

IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9649MR)

This product GTTS-WQ9649MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 608
UniProt ID P07766; Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9649MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6070MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ9044MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ8171MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ14550MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ9729MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ15304MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ7723MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ12130MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW